ArticleClinical rheumatology2025
Diagnostic delay in patients with psoriatic arthritis from dermatology and rheumatology clinics: a medical record review study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex, Sex Hormones and Inflammatory Burden and Cardiovascular Risk in Patients with Spondyloarthritis.Biomolecules · 2026Review
- Diagnostic delay in psoriatic disease: cutaneous and musculoskeletal pathways in a Mexican tertiary-care cohort.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the diagnostic delay in patients with psoriatic arthritis (PsA) attending dermatology and rheumatology clinics.
methodsTwo cohorts of patients with an established diagnosis of PsA from four dermatology clinics and two rheumatology clinics in Shanghai between February 2019 and January 2022 were retrospectively analyzed. Diagnostic delay was defined as the time from the onset of PsA-related musculoskeletal symptoms to PsA diagnosis. Diagnostic delay was compared by sex and arthritis type within each cohort. The cumulative diagnosis rates of PsA in both cohorts were also analyzed.
resultsThe dermatology and rheumatology cohorts included 109 and 119 patients with PsA, respectively. The median diagnostic delay was significantly longer in the dermatology cohort than in the rheumatology cohort (median [IQR]: 45.5 [68.3] vs. 16.5 [25.6] months). Within each cohort, there were no significant differences in diagnostic delay between sexes. In the dermatology cohort, patients with pure axial PsA experienced a longer diagnostic delay than those with the peripheral type (median [IQR]: 57 [130] vs. 37 [66] months). Approximately 30% of PsA patients in the dermatology cohort had a diagnostic delay exceeding 6 years. In contrast, in the rheumatology cohort, no patient with PsA experienced a diagnostic delay of more than 5 years, with cumulative diagnosis rates of 39%, 58.5%, 84.8%, 96.7%, and 100% at < 1 year, < 2 years, < 3 years, < 4 years, and < 5 years, respectively.
conclusionPatients with PsA attending dermatology clinics experience significantly longer diagnostic delays compared to those attending rheumatology clinics.
Indexed as
Identifiers
40571883What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.